EZH2抑制は,脳芽細胞依存経路を通じて,多発性骨髄腫における免疫調節薬剤耐性を克服する
Yigen Li1, Amy Wilson1, Yakinthi Chrisochoidou1
1The Institute of Cancer Research.
Haematologica
|February 12, 2026
まとめ
EZH2阻害剤とIMiD/CELMoDを併用すると,IRF4発現を低下させ,細胞死亡を誘発することで,多発性骨髄腫における一次抵抗を克服します. この戦略は,治療結果を改善するための主要な経路をターゲットにしています.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- ドラッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー
背景:
- 免疫調節剤 (IMiDs) とセレブロン (CRBN) E3リガース調節剤 (CELMoDs) は,多発性骨髄腫 (MM) の効果的な治療法である.
- 治療抵抗性 (原発性および獲得性) は,MM治療における重要な課題であり続けています.
- ゼステホモログ2 (EZH2) のエンハンサーは,再発性MMでは上調され,より短い進行性生存率と関連しています.
研究 の 目的:
- 主要なIMiD耐性多発性骨髄腫のモデルにおいて,EZH2阻害剤とIMiD/CELMoDを併用する有効性を調査する.
- この組み合わせ療法によって誘発されるシナージティックな細胞死の原因となるメカニズムを解明する.
主な方法:
- 主要なIMiD耐性のモデルとして,KMS-11とRPMI-8226の骨髄腫細胞系を利用した.
- タゼメトスタット (EZH2阻害剤) をIMiD/CELMoDと併用して投与した.
- 評価されたインターフェロン調節因子4 (IRF4) 発現,細胞活性,アポトーシス,およびCRBN依存性.
主要な成果:
- 併用療法により,耐性細胞系におけるIRF4発現が著しく低下しました.
- シンジェスティックなアポトーシスと細胞死が観察され,プライマリIMiD抵抗を克服しました.
- シネージー効果はCRBNに依存し,IRF4過剰表現によって逆転した.
- 機械的に,タゼメトスタートは,IRF4プロモーターへのIKZF1結合を減少させ,IMiDs/CELMoDsの抑制効果を高めました.
結論:
- EZH2阻害をIMiD/CELMoDと組み合わせることで,多発性骨髄腫におけるIMiD原発性耐性を克服するための有望な戦略が提供されます.
- このアプローチは,IRF4経路を標的にして,抗骨髄腫作用の相乗効果をもたらします.
- IMiD耐性を持つMM患者の治療のためにさらなる臨床試験が必要である.
関連する概念動画
Drug Dependence
1.7K
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
1.7K
NF-κB-dependent Signaling Pathway
10.1K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
10.1K
cAMP-dependent Protein Kinase Pathways
8.6K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.6K
Bioequivalence of Drugs: Drugs with Multiple Indications
165
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
165
Feedback Inhibition
57.3K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
558
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
558


